{
    "nctId": "NCT06142344",
    "briefTitle": "Radioembolisation and Chemotherapy in Liver Metastatic Breast Cancer Patients",
    "officialTitle": "The Added Value of 166Ho Trans-arterial Radioembolization to Systemic Therapy in Liver Metastatic Breast Cancer Patients",
    "overallStatus": "RECRUITING",
    "conditions": "Liver Metastases, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 13,
    "primaryOutcomeMeasure": "Feasibility",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women \\>18 years\n* Patients with hormone positive and HER2 negative liver metastatic breast cancer\n* No extra-hepatic disease progression at evaluation of at least second line systemic chemotherapy\n* Suitable for TARE evaluated after the mapping angiography\n* Measurable target tumors in the liver according to RECIST 1.1\n* Liver tumor burden \\<50 %\n* ECOG performance score 0 to 1\n* Laboratory parameters: neutrophils \\>1000/\u03bcL; thrombocyte count \\>1000000 \u03bcL; eGFR \\>45/mL/min/1.73 m2; albumin \\> 3.0 g/dl, bilirubin \\< 1.5x ULN (unless Gilbert syndrome); aminotransferase (ALAT/ASAT) \\<3.0 ULN\n* Able to read Dutch\n\nExclusion Criteria:\n\n* Life expectancy \u22643 months\n* Patient eligible for other curative local liver therapy (ea. surgery, ablation)\n* Brain, pleural, peritoneal or extensive extra-hepatic visceral metastases\n* Other life-threatening disease (i.e. Dialysis, unresolved diarrhea, serious unresolved infections (HIV, HBV, HCV etc.))\n* Contraindication for angiography or MRI\n* Significant toxicities due to prior cancer therapy that have not resolved before the initiation of the study, if the investigator determines that the continuing complication will compromise the safe treatment of the patient\n* Prior or planned embolic intra-arterial liver directed therapy (TACE, TAE, TARE)\n* Prior or planned external or internal radiation therapy of the liver\n* Cirrhosis or portal hypertension\n* Main portal vein thrombosis\n* Intervention for, or compromise of, the Ampulla of Vater\n* Ascites (except minor focal ascites)\n* Baseline use of analgesics for abdominal pain\n* Pregnancy (Women at childbearing potential need at least one form of birth control) and breastfeeding\n* Flow to extra hepatic vessels not correctable by reposition or embolization\n* Estimated dose to the lungs greater than 30 Gy in a single administration or 50 Gy cumulatively\n* Target tumoral absorbed dose of \\< 90Gy or an absorbed dose to the normal liver parenchyma of \\>50Gy (in case of whole liver treatment)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}